Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study-Reference-Cited by-同舟云学术

Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study

Published:2015-10 Issue:1 Volume:139 Page:17-22
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Ferriss James S.^ORCID,Java James J.,Bookman Michael A.,Fleming Gini F.,Monk Bradley J.,Walker Joan L.,Homesley Howard D.,Fowler Jeffrey,Greer Benjamin E.,Boente Matthew P.,Burger Robert A.

Funder

National Cancer Institute

Gynecologic Oncology Group Administrative Office

Gynecologic Oncology Group Statistical and Data Center

NRG Oncology SDMC

NRG Oncology Operations

GOG Young Investigator Award.

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference30 articles.

1. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup;Bookman;J. Clin. Oncol.,2009

2. Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer: association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model;Akutagawa;Jpn. J. Cancer Res.,2002

3. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer;Yabushita;Oncol. Rep.,2003

4. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion;Belotti;Mol. Cancer Res.,2008

5. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease;Kraft;Cancer,1999

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFNβ induces an anti-tumor immune response in high grade serous ovarian cancer;Neoplasia;2024-11

2. Outcome and prognostic factors of low‑grade serous ovarian cancer: An observational retrospective study;Molecular and Clinical Oncology;2024-05-22

3. Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial;Translational Oncology;2024-05

4. Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer;Critical Reviews in Oncology/Hematology;2024-02

5. The complex role of IL-10 in malignant ascites: a review;Cancer Immunology, Immunotherapy;2024-01-27